Bionxt Solutions Advances Toward Human Trials for MS Therapy

Biotechnology firm Bionxt Solutions has moved a step closer to testing a novel multiple sclerosis treatment in humans. The company’s latest preclinical data indicates its proprietary oral film technology could offer a significant improvement over existing drug delivery methods for the established MS medication, Cladribin.

The company is developing several platforms for more precise drug administration, including transdermal systems. Its primary focus is on neurological and immunological conditions, where conventional oral tablets often present challenges. For many patients with multiple sclerosis, swallowing difficulties or gastrointestinal side effects from standard tablets are a considerable issue. Bionxt’s sublingual film, which dissolves under the tongue, is designed to bypass the digestive Read more...